Microarray data is available from the NCBI Gene Expression Omnibus. The accession number is GSE66465. (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66465>).

Introduction {#sec005}
============

IgG4-related disease (IgG4-RD) is a new emerging disease entity characterized by elevated serum IgG4 concentrations and tissue tumefaction or infiltration by IgG4-positive plasma cells \[[@pone.0126582.ref001], [@pone.0126582.ref002]\]. Clinically, IgG4-RD is characterized by a general inflammatory state as well as manifestations specific to individual affected organs, including the lacrimal glands, salivary glands, pancreas, bile duct, lungs, liver, kidneys, prostate, thyroid, retroperitoneum, arteries, lymph nodes, skin, central nervous system, and breasts. Most patients with IgG4-RD experience multiple organ involvement, either synchronously or metachronously, whereas others show only a single site of involvement \[[@pone.0126582.ref001], [@pone.0126582.ref002]\]. IgG4-RD occurs more frequently in older adults than in younger individuals (median age, 58 years). Once it occurs, it slowly progresses and is characterized by elevated serum IgE \[[@pone.0126582.ref003]\] and relatively weak indicators of inflammation, such as low titer of CRP\[[@pone.0126582.ref004]\]. Steroid therapy has been found effective in most patients \[[@pone.0126582.ref003], [@pone.0126582.ref005]\].

IgG4-RD is also characterized by several aberrant findings in the acquired immune system. For example, the numbers of CD4^+^CD25^+^Foxp3^+^ regulatory T cells (Tregs) in affected tissues and peripheral blood are significantly higher in patients with IgG4-RD than in healthy controls \[[@pone.0126582.ref006]--[@pone.0126582.ref008]\]. In addition, several autoantibodies, including anti-carbonic anhydrase II and anti-lactoferrin, are often present in patients with IgG4-RD, especially those with IgG4-related autoimmune pancreatitis (AIP) \[[@pone.0126582.ref009], [@pone.0126582.ref010]\]. Furthermore, the expression of Th2 and Treg cytokines is dominant in IgG4-RD \[[@pone.0126582.ref006], [@pone.0126582.ref011], [@pone.0126582.ref012]\]. At present, however, it is not clear whether IgG4-RD is caused by abnormalities in acquired immunity like autoimmune diseases, or whether the excess production of IgG4 is a true cause of IgG4-RD or an epiphenomenon associated with inflammatory and/or allergic reactions.

Although its true etiology remains unclear, infections with various pathogens, including Helicobacter pylori \[[@pone.0126582.ref013], [@pone.0126582.ref014]\], gram-negative bacteria \[[@pone.0126582.ref015]\] and Mycobacterium tuberculosis \[[@pone.0126582.ref016]\], have been reported in patients with IgG4-RD. These pathogens may induce the production of IgG4, which, in turn, may block activation of the innate immune system by inhibiting the activities of IgG1 and the formation of immune complexes, resulting in the persistence of these infections \[[@pone.0126582.ref017]\]. We therefore attempted to identify genes of the innate immune system that are related to the pathogenesis or clinicopathology of IgG4-RD.

Initially, we utilized DNA microarray analysis to select candidate genes with levels of expression three times higher or lower in patients with IgG4-RD than in healthy controls. Subsequently we compared expression of genes in patients with IgG4-RD before and after steroid treatment to identify genes up- and down regulated by steroids. Finally, we performed transcriptome analysis of PBMCs from 27 patients with IgG4-RD and 13 healthy controls to validate the significance of these genes.

Materials and Methods {#sec006}
=====================

Patients and samples {#sec007}
--------------------

IgG4-RD was diagnosed according to the comprehensive diagnostic criteria for IgG4-RD \[[@pone.0126582.ref018]\]. These patients were registered in the research project of the Research Program for Intractable Disease of the Ministry of Health, Labor, and Welfare (MHLW) of Japan, designed to establish diagnostic criteria for IgG4-related multi-organ lymphoproliferative syndrome (IgG4-MOLPS). Initial steroid therapy for IgG4-RD consisted of prednisolone (0.6 mg/kg body weight per day), with this dose reduced 10% every 2 weeks. Two subjects with characteristic clinical features of IgG4-RD, including extreme elevation of serum IgG4 (5630 and 2950 mg/dl, respectively) and multiple organs showing tumefaction by IgG4-positive plasma cells, including the salivary glands, duodenum, lymph nodes, bile ducts, pancreas and prostate, are described in [Table 1](#pone.0126582.t001){ref-type="table"}. The IgG, IgG4, and IgE concentrations in all healthy controls were within normal ranges.

10.1371/journal.pone.0126582.t001

###### Profiles of IgG4-RD patients analyzed by DNA microarrays.

![](pone.0126582.t001){#pone.0126582.t001g}

  No             Age   Sex   IgG     Post Tx. IgG   IgG4    Post Tx. IgG4   IgE     Post Tx. IgE   Lesions
  ---- --------- ----- ----- ------- -------------- ------- --------------- ------- -------------- ----------------
  1    IgG4-RD   66    M     5,630   464            3,120   291             265.0   51.5           SG, DD, LN
  2    IgG4-RD   63    M     2,950   638            1,540   184             7.9     5.0            SG, BD, PC, PS
  3    Healthy   57    M     \-      \-             \-      \-              \-      \-             \-
  4    Healthy   58    M     \-      \-             \-      \-              \-      \-             \-
  5    Healthy   62    M     \-      \-             \-      \-              \-      \-             \-
  6    Healthy   64    M     \-      \-             \-      \-              \-      \-             \-

Patients were diagnosed according to the comprehensive diagnostic criteria for IgG4-RD \[[@pone.0126582.ref006]\] and were subsequently treated with steroids. IgG(mg/dL), IgG4(mg/dL), IgE(IU/mL). Abbreviations: SG, salivary gland; DD, duodenum; LN, lymph node; BD, bile duct; PC, pancreas; PS, prostate.

For DNA microarray, heparinized peripheral blood was obtained from these two IgG4-RD patients before and 3 months after starting steroid therapy and from four healthy normal controls (all men, median age 59 years). For validation assays, heparinized peripheral blood was obtained from 27 patients with IgG4-RD (19 men, 8 women; median age 66 years) before steroid therapy and from 13 healthy controls (9 men, 4 women; median age 61 years). Peripheral blood was also obtained from 20 patients with IgG4-RD three to six months after commencement of steroid treatment. Subject characteristics are shown in [Table 2](#pone.0126582.t002){ref-type="table"}.

10.1371/journal.pone.0126582.t002

###### Profiles of IgG4-RD patients assayed by Real time RT-PCR.

![](pone.0126582.t002){#pone.0126582.t002g}

  No        Age   Sex   IgG (mg/dL)   IgG4 (mg/dL)   IgG4(postTx)   IgE (IU/mL)   Lesion
  --------- ----- ----- ------------- -------------- -------------- ------------- --------------------
  **1\***   66    M     5,630         3,120          291            265           SG, DD, LN
  **2\***   63    M     2,950         1,540          184            7             SG, BD, PC, PS
  3         69    F     1,950         362            44             151           SG
  4         62    M     1,500         435            89             301           SG, PC, LN
  5         60    F     1,150         110            12             399           LG, SG, PC
  6         79    M     4,020         1,460          98             330           SG, RF, KN, PS, LN
  7         70    M     2,563         1,160          326            283           SG, RF, IP, UR
  8         65    M     6,786         3,880          447            673           PS, LN
  9         72    M     2,980         254            9              85            PL, RF, PC, PG, LN
  10        73    M     3,377         1,770          690            1,216         SG, PC
  11        47    F     1,365         304            35             238           LG, SG
  12        66    M     1,679         756            153            631           SG, IP
  13        53    M     1,692         313            55             494           LG, UR
  14        70    M     2,090         314            201            190           LG, SG
  15        52    F     3,038         1,300          298            327           LG, SG
  16        38    M     2,861         1,440          315            219           LG, IP
  17        66    F     3,214         1,370          174            60            LG, SG, IP, BD
  18        66    F     4,174         1,300          179            100           LG, SG, RF, IP, LN
  19        59    M     1,603         499            124            1,139         RF
  20        59    M     2,456         1,430          226            262           PC, IP
  21        74    M     3,250         788                           189           AA, LN
  22        91    M     4,577         669                           626           SG
  23        55    M     3,087         1,760                         837           PS, IP
  24        57    F     2,442         990                           1,181         SG
  25        68    F     1,620         419                           159           SG, PC
  26        71    M     1,800         373                           180           SG, PC, LN
  27        56    M     4,010         2,160                         680           LG, SG, LN

Real time RT-PCR was performed on mRNA samples isolated from the PBMCs of 27 patients (19 men, 8 women; median age 66 years) with IgG4-RD. Case 1\* and 2\* are the same patients in [Table 1](#pone.0126582.t001){ref-type="table"}. Patients with steroid treatment are Case1 to Case 20, and IgG4 (post Tx) means the value of serum IgG4 after steroid treatment. Abbreviations: SG, salivary gland; DD, duodenum; LN, lymph node; BD, bile duct; PC, pancreas; PS, prostate; AA, aorta abdominalis; IP, interstitial pneumonia; LG, lacrimal gland; RF, retroperitoneal fibrosis; KN, kidney; UR, ureter; PL, pleura; PG, pituitary gland.

This study was approved by the institutional ethics board of each institution; Kanazawa Medical University, Kanazawa University, Gunma University Graduate School of Medicine, University of Toyama, Nagaoka Red Cross Hospital, Kansai Medical University, Tokyo Metropolitan Komagome Hospital, National Hospital Organization Nagasaki Medical center, Ehime Graduate School of Medicine, Isahaya Health Insurance General Hospital, Sapporo Medical University School of Medicine, Shinshu University School Hospital, Nagasaki Graduate School of Health Sciences, University of Occupational and Environmental Health, University of Tsukuba, Mitoyo General Hospital, and Kyoto University. Informed consent for publication of all data and samples was obtained from each patient. The research was conducted in compliance with the Declaration of Helsinki.

Isolation of total RNA {#sec008}
----------------------

Immediately after blood collection, PBMCs were separated using Lymphoprep (Axis-Shield, Oslo, Norway), according to the manufacturer's instructions. Total RNA was extracted using RNeasy Plus Mini kits (Qiagen, Hilden, Germany), according to the manufacturer's protocol. The concentration and quality of these RNA samples were assessed by measuring UV absorbance at 260 and 280 nm (A~260~/~280~ ratio) and by images of 18S and 28S ribosomal bands in agarose gel electrophoresis.

DNA microarrays {#sec009}
---------------

To exclude any gender-related differences in gene expression, DNA microarray analysis was performed only on samples obtained from male patients and controls. Total RNA was reverse transcribed to cDNA using Ambion WT Expression kits (Applied Biosystems, Foster City, CA), labeled with GeneChip WT Terminal Labeling and Controls kits (Affymetrix, Santa Clara, CA), and hybridized to GeneChip Human Gene 1.0 ST Arrays (Affymetrix), which include 28869 probes. Digitalized image data were processed using GeneChip Operating Software (Affymetrix). Following background correction and 50^th^ percentile normalization, the microarray results were analyzed using GeneSpring version 11.0 software (Agilent Technologies, Santa Clara, CA). The microarray expression data discussed in this paper ([S1 Table](#pone.0126582.s001){ref-type="supplementary-material"}) have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible with GEO Series accession number GSE66465 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66465>).

Genes showing ≥ 3-fold differences in expression between patients and healthy controls, and before and after steroid therapy in IgG4-RD patients, were selected, and statistically processed by K-means clustering. In addition to clustering, average fold changes were determined to screen for genes with altered levels of expression. Gene pathway databases were assessed by Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, CA) \[[@pone.0126582.ref019], [@pone.0126582.ref020]\].

Real-time PCR {#sec010}
-------------

Total RNA from PBMCs was reverse transcribed to cDNA using Sensiscript RT kits (Qiagen, Hilden, Germany) and oligo (dT) primers according to the manufacturer's instructions. Primers and TaqMan probes were purchased from Applied Biosystems. Real-time PCR was performed with an ABI Prism 7700 Sequence Detector (Applied Biosystems), using a TaqMan gene expression assay (Applied Biosystems) and Thunderbird Probe qPCR mix (Toyobo, Osaka, Japan). The relative quantity of each target mRNA was normalized relative to that of the internal control, β-actin.

Statistical analyses {#sec011}
--------------------

In real-time PCR analysis, between-group comparisons were performed using the Mann---Whitney U-test or Student's *t* test. All statistical analyses were performed using Stat View version 5.0. In all analyses, *P* \< 0.05 was defined as statistically significant.

Results {#sec012}
=======

DNA microarray analysis {#sec013}
-----------------------

DNA microarray analysis was performed to identify candidate genes that may be involved in IgG4-RD pathogenesis ([S1 Table](#pone.0126582.s001){ref-type="supplementary-material"}). Total RNA was prepared from PBMCs of two patients with IgG4-RD ([Table 1](#pone.0126582.t001){ref-type="table"}) and from four healthy controls and reverse transcribed. Genes showing ≥3-fold differences in expression between patients, regardless of steroid treatment, and controls were identified, inasmuch as they may be congenitally altered in patients with IgG4-RD and may be responsible for the pathogenesis of this disease. The average values of the four data sets from the two patients with IgG4-RD before and after steroid treatment, and of the four data sets from healthy volunteers, were classified by K-means clustering followed by separation based on 3-fold changes in level of expression. This method identified 21 genes that showed ≥ 3-fold differences in level of expression between IgG4-RD patients (both before and after steroid treatment) and healthy controls ([Table 3](#pone.0126582.t003){ref-type="table"}). Five of these genes were decreased in IgG4-RD patients, including those encoding Charcot---Leyden crystal protein (CLC), desmocollin1 (DSC1), interleukin 8 receptors alpha (IL8RA) and beta (IL8RB), and leucine rich repeat neuronal 3 (LRRN3), whereas 16 were increased in IgG4-RD ([Table 3](#pone.0126582.t003){ref-type="table"}). Ingenuity Pathways Analysis (Ingenuity Systems) \[[@pone.0126582.ref019], [@pone.0126582.ref020]\] confirmed that no reported changes in expression of these genes were associated with steroid treatment (data not shown).

10.1371/journal.pone.0126582.t003

###### Genes showing ≥3-fold differences in expression level in IgG4-RD patients and healthy controls.
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  Transcripts Cluster Id                              Regulation   Gene symbol       Gene description
  --------------------------------------------------- ------------ ----------------- -------------------------------------------------
  [\*](#t003fn002){ref-type="table-fn"} **8036755**   **down**     **CLC**           **Charcot-Leyden crystal protein**
  8022728                                             down         DSC1              desmocollin 1
  [\*](#t003fn002){ref-type="table-fn"} **8058905**   **down**     **IL8RA**         **interleukin 8 receptor, alpha**
  [\*](#t003fn002){ref-type="table-fn"} **8048227**   **down**     **IL8RB**         **interleukin 8 receptor, beta**
  8135488                                             down         LRRN3             leucine rich repeat neuronal 3
  7981708                                             up           IGHE              immunoglobulin heavy constant epsilon
  8095736                                             up           AREG\|LOC727738   amphiregulin (schwannoma-derived growth factor)
  8095744                                             up           AREG\|LOC727738   amphiregulin (schwannoma-derived growth factor)
  8101322                                             up           MOP-1             
  8055952                                             up           NR4A2             nuclear receptor subfamily 4, group A, member 2
  8156848                                             up           NR4A3             nuclear receptor subfamily 4, group A, member 3
  8012349                                             up           PER1              period homolog 1 (Drosophila)
  7908388                                             up           RGS1              regulator of G-protein signaling 1
  8005547                                             up           SNORD3A           small nucleolar RNA, C/D box 3A
  8005553                                             up           SNORD4A           small nucleolar RNA, C/D box 4A
  8013323                                             up           SNORD5A           small nucleolar RNA, C/D box 5A
  8013325                                             up           SNORD6A           small nucleolar RNA, C/D box 6A
  8013329                                             up           SNORD7A           small nucleolar RNA, C/D box 7A
  7922416                                             up           SNORD75           small nucleolar RNA, C/D box 75
  7982597                                             up           THBS1             thrombospondin 1
  8116992                                             up           UNQ9364           FLFF9364

We identified 21 genes showing a ≥3-fold increase (16 genes) or decrease (5genes) in expression level among 4 samples from 4 healthy controls and 2 IgG4-RD patients before and after therapy.

\*processed to the validation.

To identify genes affected by steroid treatment, transcriptomes in IgG4-RD patients were compared before and after steroid therapy. Average values from two typical IgG4-RD patients with extreme elevation of serum IgG4 and multiple organ involvement ([Table 1](#pone.0126582.t001){ref-type="table"}) and from four healthy volunteers were compared. Thirty-six genes showed ≥ 3-fold differences in expression before and after steroid therapy of IgG4-RD patients ([Table 4](#pone.0126582.t004){ref-type="table"}). For example, steroid therapy decreased the expression of IFI44L, SNORA42, and HIST1H2BB, while increasing the expression of the other genes including membrane-spanning 4-domains, subfamily A, member 3 (MS4A3), defensin alpha 3 (DEFA3) and alpha 4 (DEFA4). K-means clustering, used for statistical processing of disease-associated genes showing lower expression prior to steroid treatment and higher expression after treatment, identified 30 genes, all of which were increased ≥3-fold following steroid therapy ([Table 5](#pone.0126582.t005){ref-type="table"}). These genes may be markers of patient recovery, because their levels of expression correlated with steroid treatment.

10.1371/journal.pone.0126582.t004

###### Genes showing ≥3-fold changes in expression in IgG4-RD patients in response to steroid therapy.
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  Transcripts    Cluster ID                                          Case1 FC        Case 2 FC        Gene symbol    Gene description
  -------------- --------------------------------------------------- --------------- ---------------- -------------- ------------------------------------------------------------
  **Decrease**                                                                                                       
                 7902541                                             6.073982        3.3045993        IFI44L         interferon-induced protein 44-like
                 7920873                                             5.086785        3.571676         SNORA42        small nucleolar RNA, H/ACA box 42
                 8124394                                             4.4283495       6.986072         HIST1H2BB      histone cluster 1, H2bb
  **Increase**                                                                                                       
                 7922976                                             4.3904357       3.8047059        PTGS2          prostaglandin-endoperoxide synthase 2
                 7933872                                             4.3444343       4.182845         EGR2           early growth response 2
                 [\*](#t004fn002){ref-type="table-fn"} **7940216**   **27.282946**   **22.44819**     **MS4A3**      **membrane-spanning 4-domains, subfamily A, member 3**
                 7948444                                             5.2985225       6.0289493        TCN1           transcobalamin I
                 7951246                                             35.18979        20.34096         MMP8           matrix metallopeptidase 8
                 7969288                                             44.24184        3.3508606        OLFM4          olfactomedin 4
                 7973105                                             6.7971625       5.0625668        RNASE3         ribonuclease, RNase A family, 3
                 7978351                                             11.790634       3.3185043        CTSG           cathepsin G
                 7995237                                             8.0480795       14.685388        ERAF           erythroid associated factor
                 8015991                                             3.9202752       5.3016458        SLC4A1         solute carrier family 4, anion exchanger, member 1
                 8016932                                             8.801972        4.1204348        MPO            myeloperoxidase
                 8021645                                             4.3249626       4.259984         SERPINB10      serpin peptidase inhibitor, clade B (ovalbumin), member 10
                 8029098                                             15.656315       7.720778         CEACAM6        carcinoembryonic antigen-related cell adhesion molecule 6
                 8036755                                             4.2519445       13.180141        CLC            Charcot-Leyden crystal protein
                 8037222                                             23.474125       13.198722        CEACAM8        carcinoembryonic antigen-related cell adhesion molecule 8
                 8037298                                             8.516854        8.1878           LOC100130904   similar to CD177 molecule
                 8054722                                             7.441816        8.529232         IL1B           interleukin 1, beta
                 8062444                                             8.891481        11.64061         BPI            bactericidal/permeability-increasing protein
                 8066493                                             6.6776667       5.0690618        SLPI           secretory leukocyte peptidase inhibitor
                 8086607                                             6.1559343       4.076412         LTF            lactotransferrin
                 8100994                                             7.2271314       3.2157035        CXCL2          chemokine (C-X-C motif) ligand 2
                 8122058                                             5.4273343       3.2703066        ARG1           arginase, liver
                 8126905                                             10.53019        13.541852        CRISP3         cysteine-rich secretory protein 3
                 8145281                                             5.086257        4.649192         SLC25A37       solute carrier family 25, member 37
                 8145291                                             4.369647        3.5463853        SLC25A37       solute carrier family 25, member 37
                 [\*](#t004fn002){ref-type="table-fn"} **8149109**   **27.479057**   **15.6270685**   **DEFA4**      **defensin, alpha 4, corticostatin**
                 8149116                                             69.414474       54.943527        DEFA1          defensin, alpha 1
                 8149126                                             69.360466       54.966377        DEFA1          defensin, alpha 1
                 [\*](#t004fn002){ref-type="table-fn"} **8149137**   **69.42058**    **55.047955**    **DEFA3**      **defensin, alpha 3,**
                 8151592                                             7.4683266       22.69821         CA1            carbonic anhydrase I
                 8158167                                             6.812407        3.5723207        LCN2           lipocalin 2
                 8173135                                             5.2392645       9.046565         ALAS2          aminolevulinate, delta-, synthase 2
                 8177222                                             4.341619        5.943259         CD24           

We identified 36 genes showing ≥3-fold increase or decrease in expression in IgG4-RD patients in response to steroid therapy. IFI44L, SNORA42 and HIST1H2BB had decreased expression by steroid therapy, and the other genes increased. Abbreviations: FC, fold changes.

\*processed to the validation.

10.1371/journal.pone.0126582.t005

###### The list of disease-associated genes using K-means clustering.
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  Transcripts Cluster ID                              Gene symbol    Gene description
  --------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------
  [\*](#t005fn002){ref-type="table-fn"} **7940216**   **MS4A3**      **membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific)**
  7946033                                             HBB            hemoglobin, beta
  7948444                                             TCN1           transcobalamin I (vitamin B12 binding protein, R binder family)
  7951246                                             MMP8           matrix metallopeptidase 8 (neutrophil collagenase)
  7969288                                             OLFM4          olfactomedin 4
  7973105                                             RNASE3         ribonuclease, RNase A family, 3 (eosinophil cationic protein)
  7978351                                             CTSG           cathepsin G
  7991762                                             HBA1\|HBA2     hemoglobin, alpha 1 \| hemoglobin, alpha 2
  7991766                                             HBA1\|HBA2     hemoglobin, alpha 1 \| hemoglobin, alpha 2
  7995237                                             ERAF           erythroid associated factor
  8015991                                             SLC4A1         solute carrier family 4, anion exchanger, member 1 (erythrocyte membrane protein band 3, Diego blood group)
  8016932                                             MPO            myeloperoxidase
  8021645                                             SERPINB10      serpin peptidase inhibitor, clade B (ovalbumin), member 10
  8029098                                             CEACAM6        carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)
  8037222                                             CEACAM8        carcinoembryonic antigen-related cell adhesion molecule 8
  8037298                                             LOC100130904   similar to CD177 molecule
  8062444                                             BPI            bactericidal/permeability-increasing protein
  8066493                                             SLPI           secretory leukocyte peptidase inhibitor
  8086607                                             LTF            lactotransferrin
  8122058                                             ARG1           arginase, liver
  8126905                                             CRISP3         cysteine-rich secretory protein 3
  8145281                                             SLC25A37       solute carrier family 25, member 37
  8145291                                             SLC25A37       solute carrier family 25, member 37 \| hypothetical protein LOC100133914
  [\*](#t005fn002){ref-type="table-fn"} **8149109**   **DEFA4**      **defensin, alpha 4, corticostatin**
  8149116                                             DEFA1          defensin, alpha 1 defensin, alpha 3, neutrophil-specific
  8149126                                             DEFA1          defensin, alpha 1 defensin, alpha 3, neutrophil-specific
  [\*](#t005fn002){ref-type="table-fn"} **8149137**   **DEFA3**      **defensin, alpha 3, neutrophil-specific defensin, alpha 1 \|defensin, theta 1 pseudogene**
  8151592                                             CA1            carbonic anhydrase I
  8173135                                             ALAS2          aminolevulinate, delta-, synthase 2
  8177222                                             CD24           

K-means clustering was used for statistical processing of disease-associated genes, we identified 30 genes. All genes had increased expression level by steroid therapy.

\*processed to the validation.

Real-time PCR validation {#sec014}
------------------------

Infections with various pathogens, including *Helicobacter pylori* \[[@pone.0126582.ref013], [@pone.0126582.ref014]\], gram-negative bacteria \[[@pone.0126582.ref015]\] and *Mycobacterium tuberculosis* \[[@pone.0126582.ref016]\], have been reported in patients with IgG4-RD. Therefore, we selected, from among the genes identified by DNA microarray analysis, several related to innate immunity, including those encoding CLC, also called galectin 10, IL8RA and IL8RB ([Table 3](#pone.0126582.t003){ref-type="table"}), membrane-spanning 4-domains, subfamily A, member 3 (MS4A3) and defensins alpha 3 (DEFA3) and 4 (DEFA4) (Tables [4](#pone.0126582.t004){ref-type="table"} and [5](#pone.0126582.t005){ref-type="table"}), and performed real-time RT-PCR to assess their levels of expression. We found that the levels of expression of CLC, MS4A3, DEFA3, DEFA4, IL8RA and IL8RB mRNAs were all lower in IgG4-RD patients than in healthy controls ([Fig 1](#pone.0126582.g001){ref-type="fig"}).

![Comparison of gene expression between patients with IgG4-RD and healthy controls.\
Relative expression of genes in PBMCs from 27 patients with IgG4-RD and 20 healthy controls. (A) CLC; Charcot---Leyden crystal protein. (B) IL8RA; interleukin 8 receptor alpha. (C) IL8RB; interleukin 8 receptor beta. (D) MS4A3; membrane-spanning 4-domain subfamily A member 3. (E) DEFA3; defensin alpha 3. (F) DEFA4; defensin alpha 4. Expression of all genes was significantly lower in PBMCs from untreated IgG4-RD patients than from healthy controls (p\< 0.01).](pone.0126582.g001){#pone.0126582.g001}

We also assessed the effects of steroid therapy on the levels of expression of these genes. Steroid therapy had no effects on the expression levels of the genes encoding CLC, IL8RA and IL8RB (Fig [2A](#pone.0126582.g002){ref-type="fig"}--[2C](#pone.0126582.g002){ref-type="fig"}), but significantly increased the levels of expression of the genes encoding MS4A3, DEFA3 and DEFA4 (Fig [2D](#pone.0126582.g002){ref-type="fig"}--[2F](#pone.0126582.g002){ref-type="fig"}).

![Gene expression in PBMCs from 20 patients with IgG4-RD, before and after steroid treatment.\
(A) CLC; Charcot---Leyden crystal protein. (B) IL8RA; interleukin 8 receptor alpha. (C) IL8RB; interleukin 8 receptor beta. (D) MS4A3; membrane-spanning 4-domain subfamily A member 3. (E) DEFA3; defensin alpha 3. (F) DEFA4; defensin alpha 4. Levels of CLC, IL8RA and IL8RB mRNA were not altered in IgG4-RD patients by steroid therapy (A-C), whereas those of MS4A3, DEFA3 and DEFA4 were significantly increased following steroid therapy (D-F, p\<0.01).](pone.0126582.g002){#pone.0126582.g002}

Discussion {#sec015}
==========

Elevated serum IgG4 concentration and tissue infiltration by IgG4-positive cells are key events in IgG4-RD. IgG4 itself may play anti-inflammatory rather than proinflammatory roles due to its unique structure and functions. For example, the interactions of IgG4 with the Fcγ receptor and C1q are weaker than those of the other immunoglobulin subclasses \[[@pone.0126582.ref021]\]. Moreover, IgG4 antibodies can exchange Fab arms by swapping a heavy chain and its attached light chain \[[@pone.0126582.ref022]\], thus functioning as bispecific, as well as monospecific, molecules. These properties may protect against type I allergy by inhibiting IgE function, and may prevent type II and III allergies in patients with autoimmune diseases by blocking the Fc-mediated effector functions of IgG1 and inhibiting the formation of large immune complexes \[[@pone.0126582.ref021], [@pone.0126582.ref022]\].

It is not clear, however, whether IgG4 itself is the major factor involved in the pathogenesis of IgG4-RD. Efforts have therefore been made to identify more important upstream pathogenetic changes. Abnormalities in the acquired immune system have been observed in patients with IgG4-RD, such as increased numbers of Tregs in peripheral blood and focal lesions, including the organs involved in IgG4-RD, increases associated with the etiopathogenesis of IgG4-RD \[[@pone.0126582.ref007], [@pone.0126582.ref008]\]. Increases in Tregs have been associated with increased production of Th2 cytokines, especially IL-10, which increases IgG4 production by B cells, and TGF-β, which induces the characteristic fibrotic features of IgG4-RD \[[@pone.0126582.ref006]\]. However, the mechanisms responsible for the increases in Tregs and Th2 cytokines remain unclear. We therefore attempted to identify genes that may be associated with disease etiology or pathogenesis by DNA microarray analysis of PBMCs from two patients with IgG4-RD ([S1 Table](#pone.0126582.s001){ref-type="supplementary-material"}).

Among the genes showing ≥3-fold differences in expression between IgG4-RD patients and controls, we selected CLC because of its clinical association with type I hypersensitivity such as bronchial asthma \[[@pone.0126582.ref023], [@pone.0126582.ref024]\]. Furthermore, CLC protein has been reported to be a marker of chemoattractant receptor homologous molecule expressed on T-helper type 2 cells (CRTH2), a prostaglandin D2 receptor \[[@pone.0126582.ref025]\], and CLC expression has been observed in the cytoplasm of CD4^+^CD25^+^ Tregs, with little expression in CD4^+^CD25^-^T cells \[[@pone.0126582.ref026]\]. We found that the level of CLC mRNA was significantly lower in IgG4-RD patients than in controls ([Fig 1](#pone.0126582.g001){ref-type="fig"}), despite the serum IgE concentrations being higher in IgG4-RD patients ([Table 2](#pone.0126582.t002){ref-type="table"}). These findings suggested that the elevated serum IgE observed in IgG4-RD patients may not be due to type I hypersensitivity.

In addition, inhibition of CLC expression in Tregs in vitro has been reported to lead to the proliferation of CD4^+^ T cells when co-cultured with Tregs, as well as augmenting the proliferation of the Tregs themselves. Furthermore, transfection of CLC siRNA into Tregs increased IFN-γ and TNF-α production, while having no effect on surface markers and transcription factors, such as CD25, CTLA-4, CD45RO, CD62L, and Foxp3 \[[@pone.0126582.ref026]\]. A mutation in the Foxp3 gene was found to lead to immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome in humans, and to various autoimmune, inflammatory, and allergic conditions in scurfy mice, with lymphocyte infiltration into multiple organs, and the development of hyper-IgE-emia \[[@pone.0126582.ref027], [@pone.0126582.ref028]\]. The phenotypes of mice with abnormal Treg functions were similar to those of patients with IgG4-RD. Thus, a decrease in Treg function resulting from the reduced expression of CLC, despite the increase in number of Tregs, may be related to the etiopathogenesis of IgG4-RD. We also found that the levels of expression of the IL-8 receptors, IL8RA and IL8RB, were significantly lower in untreated IgG4-RD patients than in healthy controls ([Fig 1](#pone.0126582.g001){ref-type="fig"}), with steroid therapy having no effect in the former ([Fig 2](#pone.0126582.g002){ref-type="fig"}). Stimulation by inflammatory cytokines, such as IL-1, tumor necrosis factor (TNF)-α, and IL-8, induces chemokine production by monocytes and macrophages. These chemokines play a major role in the innate immune system, by promoting neutrophil migration and activation. Since neutrophil migration is abrogated at the site of inflammation in IL-8R knockout mice \[[@pone.0126582.ref029], [@pone.0126582.ref030]\], decreased expression of IL8RA and IL8RB may be involved in impaired innate immune system.

As IgG4 itself may play anti-inflammatory roles due to its unique properties, we selected three genes showing increased expression in IgG4-RD patients after steroid therapy, i.e. MS4A3, DEFA3 and DEFA 4. MS4A3, also called HTm4, belongs to the MS4A family, which includes CD20 (MS4A1) and Fcε RI antigen receptor β-chain (MS4A2). These proteins have four transmembrane domains in their N-terminal regions and act as cell surface signaling molecules and intercellular proteins, as well as having C-terminal cytoplasmic regions \[[@pone.0126582.ref031]\]. Among cells of the hematopoietic system, basophils show the highest level of MS4A3 expression, with other granulocytes and B and T cells also showing expression at lower levels \[[@pone.0126582.ref031]\]. Chromosomally, the MS4A3 gene is located adjacent to the gene encoding Fcε RI antigen receptor β-chain (MS4A2), which is thought to be involved in type I allergic reactions \[[@pone.0126582.ref032]\]. Although MS4A3 was thought to be associated with elevated serum IgE and allergic rhinitis, we found that its level of expression was significantly lower in PBMCs from IgG4-RD patients prior to steroid treatment than from healthy controls ([Fig 1](#pone.0126582.g001){ref-type="fig"}), and that its level of expression in IgG4-RD patients increased after steroid treatment ([Fig 2](#pone.0126582.g002){ref-type="fig"}). Although expression of MS4A3 may be diagnostic of IgG4-RD, further studies are required to determine their association.

We also found that the expression of the DEFA3 and DEFA4 genes was lower in patients with IgG4-RD than in controls ([Fig 1](#pone.0126582.g001){ref-type="fig"}). Defensin is a representative antibacterial peptide in mammals, with its antibacterial activity functioning as an effector in the innate immune system \[[@pone.0126582.ref033]\]. Human neutrophils express both α- and β-defensin, with 5%-7% of the total protein in these cells being human neutrophil peptides-3 and -4, which are encoded by the DEFA3 and DEFA4 genes, respectively, with these proteins also being present in azurophil granules \[[@pone.0126582.ref033]\]. Moreover, defensin is produced not only by neutrophils, but by phagocytic cells, lymphocytes and epithelial cells \[[@pone.0126582.ref034]\]. In addition, α-defensin acts to mobilize dendritic and T cells to sites of bacterial invasion, thereby serving as an intermediary between the innate and acquired immune systems \[[@pone.0126582.ref033], [@pone.0126582.ref035]\].

Our analysis of gene expression in response to steroid treatment showed that the levels of expression of genes encoding bactericidal substances, such as myeloperoxidase, cathepsin G, bactericidal/permeability-increasing protein and lactotransferrin, were lower in IgG4-RD patients prior to steroid treatment than in healthy controls ([Table 5](#pone.0126582.t005){ref-type="table"}). Our findings, that the levels of expression of α-and β-defensin ([Table 5](#pone.0126582.t005){ref-type="table"}) and of IL8RA and IL8RB ([Table 3](#pone.0126582.t003){ref-type="table"}) were lower in PBMCs from IgG4-RD patients than from controls, suggest that functions of innate immunity may be impaired in IgG4-RD patients. Thus impaired transition from innate to acquired immunity may be related to the etiopathogenesis of IgG4-RD.

Assessment of tissue lesions from patients with IgG4-RD showed that the levels of expression of the Th1 cytokine, IFN-γ, and the Th2 and inhibitory cytokines, IL-10 and transforming growth factor-β (TGF-β), were all elevated compared with healthy controls \[[@pone.0126582.ref006]\]. Our gene cluster analysis, however, did not find ≥ 3-fold differences in the levels of expression of inhibitory cytokines associated with Treg production and function, such as TGF-β and IL-10. In contrast to the previous study, we analyzed mRNA levels in PBMCs of IgG4-RD patients, not in the lesions themselves. Therefore, the discrepancy between studies may reflect secondary changes occurring during the disease process. It is also known that RNA expression and protein levels are not always correlated in cells or the circulation. Since there is the limitation of our analysis that only two patients with IgG4-RD have been analyzed by DNA microarray, our results, showing decreased expression of innate immune system-related genes, will require further mechanistic studies.

To our knowledge, however, no previous reports have measured serum IL-10 and TGF-β concentrations in IgG4-RD patients. Thus, our results suggest that the levels of inhibitory cytokines are not increased in the peripheral blood of IgG4-RD patients.

Conclusions {#sec016}
===========

We found that the levels of expression of genes involved in allergy development and innate immunity, including those encoding CLC, MS4A3, DEFA3, DEFA4, IL8RA, and IL8RB, were lower in PBMCs from IgG4-RD patients than from healthy controls. These findings suggest that impairments in the innate immune system may be responsible, at least in part, for the pathogenesis of IgG4-RD. Stimulation of nucleotide-binding oligomerization domain (NOD)-like receptors (NLR) on monocytes was found to increase IgG4 production by B cells \[[@pone.0126582.ref036]\]. Moreover, monocytes from patients with IgG4-RD showed greater IgG4 production by B cells than monocytes from healthy individuals upon stimulation with NOD-2 ligand \[[@pone.0126582.ref036]\]. Although the mechanisms of IgG4 production and their contribution to IgG4-RD are still unclear, cross-talk between the innate and acquired immune system may play key roles in the pathogenesis of IgG4-RD \[[@pone.0126582.ref017]\].

Supporting Information {#sec017}
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###### DNA microarray analysis of two typical patients with IgG4-RD.

Total RNA was prepared from PBMCs of two patients with IgG4-RD ([Table 1](#pone.0126582.t001){ref-type="table"}) and from four healthy controls and reverse transcribed.

(XLS)

###### 

Click here for additional data file.
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